Matsumura T, Furuichi H, Izumi J, Kamatsuka Y, Takei M, Nakata N, Ito S, Suda H, Kizaki K, Kurimoto T
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Saitama, Japan.
Nihon Yakurigaku Zasshi. 1993 Mar;101(3):177-86. doi: 10.1254/fpj.101.3_177.
The anti-ischemic and anoxic effects of NC-1100, a piperazine type calcium channel blocker, were investigated in various cerebral ischemia and anoxia models in mice, gerbils and guinea pigs. Minimal effective doses of NC-1100 were 8 mg/kg, i.p. and 30 mg/kg, p.o. for KCN-induced anoxia; 16 mg/kg, i.p. for decapitation-induced gasping; 30 mg/kg, i.p. for cerebral ischemia induced by occlusion of bilateral carotid arteries in gerbils; and 10 microM for the in vitro ischemic model in hippocampal slices. Moreover, NC-1100 attenuated the disturbance of cerebral energy metabolism induced by decapitation in mice. These results suggest that NC-1100 has a cerebral protective effect, and that attributable to its ability to improve the cerebral energy metabolism disturbance.
哌嗪型钙通道阻滞剂NC - 1100的抗缺血和缺氧作用,在小鼠、沙鼠和豚鼠的各种脑缺血和缺氧模型中进行了研究。NC - 1100对氰化钾诱导的缺氧的最小有效剂量分别为腹腔注射8 mg/kg和口服30 mg/kg;对断头诱导的喘息为腹腔注射16 mg/kg;对沙鼠双侧颈动脉闭塞诱导的脑缺血为腹腔注射30 mg/kg;对海马切片的体外缺血模型为10 microM。此外,NC - 1100减轻了小鼠断头诱导的脑能量代谢紊乱。这些结果表明,NC - 1100具有脑保护作用,这归因于其改善脑能量代谢紊乱的能力。